Form 8-K · Current Report · Filed 2024-12-04
Cencora Announces Pricing of Senior Notes and Underwriting Agreement
On December 2, 2024, Cencora, Inc. priced $500 million of 4.625% Senior Notes due 2027, $600 million of 4.850% Senior Notes due 2029, and $700 million of 5.150% Senior Notes due 2035. The offering is part of an underwritten public offering, with proceeds intended for the acquisition of Retina Consultants of America and other corporate purposes. The underwriting agreement was entered into with BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The offering is expected to close on December 9, 2024.
- Filer
- Cencora Inc. COR · NYSE
- Filed
- Accession
- 0001104659-24-125357
- CIK
- 0001140859
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$250.05
Next session
-2.3%
Since filing
+24.5%
Latest close
$311.34
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from COR reporting the same item, with the next session's move:
Exhibits (2)
About Cencora Inc.
Cencora Inc., formerly known as AmerisourceBergen Corporation, represents a pivotal entity in the global healthcare distribution and services sector. As a leading pharmaceutical sourcing and distribution services company, Cencora Inc. plays a critical role in ensuring the efficient supply of pharmaceutical products to a range of healthcare providers, including hospitals, pharmacies, and clinics. Its business model is centered on the seamless integration of logistics, consulting services, and the provision of innovative solutions aimed at improving pharmaceutical supply chain operations. Cencora Inc. impacts various segments of the healthcare industry by enhancing the availability and accessibility of healthcare products. Known for its global reach and extensive network of distribution centers, the company supports the delivery of critical medications and healthcare products across numerous geographies. Cencora Inc.'s significance in the market is underscored by its ability to partner with pharmaceutical manufacturers and healthcare providers to streamline processes, reduce costs, and improve patient outcomes. Headquartered in Conshohocken, Pennsylvania, Cencora Inc. remains a cornerstone of the healthcare distribution market, focusing on sustainability, innovation, and strategic collaborations.
Never miss another COR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.